Statin therapy and cataract in type 2 diabetes;Traitement par statine et cataracte dans le diabète de type 2

Diabetes and Metabolism

Volumn 37, Issue 2, 2011, Pages 139-143

  Hermans, M P ^a   Ahn, S A ^a   Rousseau, M F ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cataract; Ezetimibe; Fibrate; Retinopathy; Side effects; Statin; Type 2 diabetes

Indexed keywords

EZETIMIBE; HEMOGLOBIN A1C; STATIN;

ADULT; ARTICLE; CATARACT; CROSS-SECTIONAL STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CATARACT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 79955057812     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.09.005     Document Type: Article

References (23)

1. Massin P., Angioi-Duprez K., Bacin F., Cathelineau B., Cathelineau G., Chaine G., et al. Detection, monitoring and treatment of diabetic retinopathy. Recommendations of ALFEDIAM. Committee of above-mentioned experts and validated by the board of directors and scientific board of ALFEDIAM. Diabetes Metab 1996, 22:203-209.
2. Massin P. Oeil et diabète. Traité de diabétologie 2005, 536-555. Médecine-Sciences Flammarion, Paris. A. Grimaldi (Ed.).
3. Klein B.E., Klein R., Lee K.E., Grady L.M. Statin use and incident nuclear cataract. JAMA 2006, 295:2752-2758.
4. Klein B.E., Knudtson M.D., Brazy P., Lee K.E., Klein R. Cystatin C, other markers of kidney disease, and incidence of age-related cataract. Arch Ophthalmol 2008, 126:1724-1730.
5. Dodson P.M. Diabetes and the eye. Diabetic retinopathy 2009, 33-44. Oxford University Press, Oxford. P.M. Dodson (Ed.).
6. de Vries A.C., Vermeer M.A., Bloemendal H., Cohen L.H. Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens. Invest Ophthalmol Vis Sci 1993, 34:377-384.
7. Stoll L.L., McCormick M.L., Denning G.M., Weintraub N.L. Antioxidant effects of statins. Drugs Today (Barc) 2004, 40:975-990.
8. Hippisley-Cox J., Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010, 340:c2197.
9. Expert Committee Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl. 1):S11-S61. American Diabetes Association.
10. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
11. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
12. Kothari V., Stevens R.J., Adler A.I., Stratton I.M., Manley S.E., Neil H.A., et al. UKPDS 60 risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002, 33:1776-1781.
13. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
14. Levy J.C., Matthews D.R., Hermans M.P. Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21:2191-2192.
15. Hermans M.P. Diabetic macro- and microvascular disease in type 2 diabetes. Diabetes Vasc Dis Res 2007, 4:S7-S11.
16. Munoko T.N., Hermans M.P. Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort. Diabetes Metab Syndr 2008, 2:115-124.
17. Hermans M.P., Ahn S.A., Rousseau M.F. Raised natriuretic peptides, Big-endothelin-1 and improved beta-cell function in type 2 diabetic males with hyperuricaemia. Diab Vasc Dis Res 2009, 6:190-193.
18. Manwa B., Kashongwe Z., Bahindwa B., Kolanowski J., Hermans M.P. Dietary cassava, beta-cell function and hyperbolic product loss rate in type 2 diabetes patients from South Kivu. Diabetes Metab 2010, 36:108-113.
19. Vinson J.A. Oxidative stress in cataracts. Pathophysiology 2006, 13:151-162.
20. Asbell P.A., Dualan I., Mindel J., Brocks D., Ahmad M., Epstein S. Age-related cataract. Lancet 2005, 365:599-609.
21. Mukesh B.N., Le A., Dimitrov P.N., Ahmed S., Taylor H.R., McCarty C.A. Development of cataract and associated risk factors: the Visual Impairment Project. Arch Ophthalmol 2006, 124:79-85.
22. Schlienger R.G., Haefeli W.E., Jick H., Meier C.R. Risk of cataract in patients treated with statins. Arch Intern Med 2001, 161:2021-2026.
23. Smeeth L., Hubbard R., Fletcher A.E. Cataract and the use of statins: a case-control study. QJM 2003, 96:337-343.